Publicaciones en colaboración con investigadores/as de University of Chicago (52)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  5. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

  6. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

    Blood cancer journal, Vol. 12, Núm. 2, pp. 32

  3. Minimally Invasive Donor Hepatectomy for Adult Living Donor Liver Transplantation An International, Multi-institutional Evaluation of Safety, Efficacy and Early Outcomes

    Annals of Surgery, Vol. 275, Núm. 1, pp. 166-174

2021

  1. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  2. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

  3. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

2020

  1. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3

  2. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

    Clinical and Applied Thrombosis/Hemostasis, Vol. 26

2018

  1. Lens regeneration in children

    Nature

  2. Pancreatic histopathology of human monogenic diabetes due to causal variants in KCNJ11, HNF1A, GATA6, and LMNA

    Journal of Clinical Endocrinology and Metabolism, Vol. 103, Núm. 1, pp. 35-45

  3. Reprogramming human T cell function and specificity with non-viral genome targeting

    Nature, Vol. 559, Núm. 7714, pp. 405-409

2017

  1. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes

    Leukemia

  2. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

    Cell, Vol. 171, Núm. 4, pp. 934-949.e15

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920